SE PUEDE YA AFIRMAR QUE TARLATAMAB ( IMDELLTRA BY AMGEN ) SUPERA AMPLIAMENTE AL LURBINECTEDIN ( ZEPZELCA BY PHARMAMAR ) TANTO EN PRIMERA LÍNEA DE MANTENIMIENTO ... COMO EN SEGUNDA LINEA PARA EL TRATAMIENTO ESTÁNDAR DE SMALL CELL LUNG CANCER EXTENSIVE-STAGE .
This subgroup analysis of the elderly population of ET743-SAR-3007 suggests that elderly patients with soft tissue sarcoma and good performance status can expect clinical benefit from trabectedin similar to that observed in younger patients. ...
